Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 26, 2007

Primary Completion Date

August 23, 2007

Study Completion Date

August 23, 2007

Conditions

Hepatic Impairment

Interventions

DRUG

Teduglutide

Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.

Trial Locations (1)

University of Miami Clinical Pharmacology Unit, Miami